Impax Laboratories Inc

Impax Laboratories — Investor Presentation (November 2006)

29 slides from Impax Laboratories's investor presentation, Nov 2, 2006

  1. Slide 1: IMPAX Laboratories, Inc.

    IMPAX Laboratories, Inc. 1 November 2006 v1 IMPAX Laboratories, Inc.

  2. Slide 2: Safe Harbor statement under the Private Securities Litigation Reform Act of 1995

    “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: Note: All product sales data included herein are derived from data published by Wolters Kluwer Health for the 12 months ending August 31, 2006, except for the veterinary product Carprofen, which are derived from data

  3. Slide 3: Company Overview

    Technology based specialty pharmaceutical company Applying oral drug delivery technology and formulation expertise to the development of generic and branded pharmaceutical products Experienced senior management team Strong product portfolio Brand strategy offers potential long-term growth opportunit

  4. Slide 4: Product Portfolio

    Approximately 108 generic products approved, pending or under development - targeting over $30 billion in US product sales 32 Approved applications 21 Applications pending at FDA 4 ANDAs with Tentative Approval Approximately 55 more under development Additional products and/or strengths Additionally

  5. Slide 5: R&D Highlights 2005

    2005 - Received 6 approvals from FDA Tentative Approval for a generic version of: Final Approvals for generic versions of: 5 November 2006 v1 IMPAX Laboratories, Inc. R&D Highlights Ditropan XL Dantrium Agrylin Rimadyl (a veterinary product) Glucophage XR 750 mg OxyContin 10, 20 & 40 mg

  6. Slide 6: Commercial Highlights 2005

    2005 - Launched 6 new products Includes generic versions of: 6 November 2006 v1 IMPAX Laboratories, Inc. Commercial Highlights Claritin-D 24 hour OxyContin 80mg CR Tablets Dantrium Capsules Agrylin Capsules Rimadyl Caplets (a veterinary product) OxyContin 10, 20 & 40mg CR Tablets

  7. Slide 7: R&D Highlights 2006 YTD

    2006 YTD - Received 3 approvals from FDA Final Approvals for generic versions of: 7 November 2006 v1 IMPAX Laboratories, Inc. R&D Highlights Salagen Colestid Granules Colestid Tablets

  8. Slide 8: Commercial Highlights 2006 YTD

    2006 YTD - Launched 4 new products Includes generic versions of: 8 November 2006 v1 IMPAX Laboratories, Inc. Commercial Highlights Salagen 5, 7.5mg Colestid Granules Lofibra 67, 134, 200mg ProAmatine 10mg

  9. Slide 9: Drug Delivery Capabilities

    Multiple delivery vehicles Applying new and existing drug delivery technologies to create new product opportunities Developing and patenting new concepts and oral controlled release technologies Approximately 120 employees in our R&D effort 9 November 2006 v1 IMPAX Laboratories, Inc. Drug Delivery C

  10. Slide 10: Development Strategy

    Target limited competition environment Generic Controlled Release – large, rapidly growing market Specialty – technically challenging projects, barriers to entry, or other selected market opportunities Brand Targeting drugs used in treating CNS disorders Focusing on improved versions of marketed com

  11. Slide 11: Development Strategy: Outsourced Development

    Outsourced Development Selected Generic Projects 22 development projects outsourced Utilizing 7 off-shore companies Provides Lower cost of development Increased development capacity 11 November 2006 v1 IMPAX Laboratories, Inc. Development Strategy

  12. Slide 12: Generic Projects: Current Status

    Current Status *US Market size, millions of US$ $17,961 55 $14,848 37 $3,113 18 Under Development $7,843 21 $7,161 10 $682 11 Pending at FDA 12 November 2006 v1 IMPAX Laboratories, Inc. Generic Projects $25,804 $22,009 $3,795 Total Market* Qty Market* Qty Market* Qty Category Total Controlled Releas

  13. Slide 13: Paragraph IV Filing Summary (22 total)

    Paragraph IV Filing Summary (22 total) *Trademarks referenced are the property of their respective owners. **Estimation based on publicly available data. Note 1 :Paragraph IV cert. & notice filed 4Q02. Products in Teal are marketed. White background means TA/FA rec’d. Initial Filing Est. Filing Orde

  14. Slide 14: Paragraph IV Filing Summary

    Paragraph IV Filing Summary *Trademarks referenced are the property of their respective owners. **Estimation based on publicly available data. Note 2 --Paragraph IV certification and notice filed 3Q05. Note 3 --May be first to file on 15 mg strength. Initial Filing Est. Filing Order** Generic of* IM

  15. Slide 15: Paragraph IV Litigation Status Summary: Resolved or Not Sued

    Paragraph IV Litigation Status Summary (22 total filed) Litigation Resolved or Not Sued (16 projects) 15 November 2006 v1 IMPAX Laboratories, Inc. Generic Projects Metformin 750mg ER Metformin 500mg ER Undisclosed Fenofibrate 54 &160mg Tabs S.E. Amphetamine 5,10,15,20,25&30mg ER Loratadine & PSE 5/1

  16. Slide 16: Paragraph IV Litigation Status Summary

    Paragraph IV Litigation Status Summary (22 total filed) Litigation Status Project 16 November 2006 v1 IMPAX Laboratories, Inc. Generic Projects Discovery stage. Trial 1H2007. Venlafaxine 37.5, 75, 150 mg ER Summary judgment motion pending. Bupropion 150 & 300mg ER (XL) Oxycodone 10, 20 & 40mg ER Lit

  17. Slide 17: Strategic Alliances for Generic Projects: Teva

    Signed June 2001 First product shipped 1Q 2004 12 Rx products 11 filed to date 11 disclosed 40 Methylphenidate 18,27,36,54 mg ER Fexofenadine/PSE 60/120 mg ER Oxybutynin 5,10,15 mg ER Bupropion 150, 300 mg ER (XL) 17 November 2006 v1 IMPAX Laboratories, Inc. Commercial Strategy Strategic Alliances f

  18. Slide 18: Strategic Alliances for Generic Projects: Dava

    Signed November 2005 Ten year exclusive agreement Payments of $60 million to be received over five years Profit split First product shipped 4Q 2005 Products Licensed: Oxycodone 10, 20 40 mg ER Oxycodone 80 mg ER 18 November 2006 v1 IMPAX Laboratories, Inc. Commercial Strategy Strategic Alliances for

  19. Slide 19: Generic Projects: Shire Settlement

    Settlement agreements signed January 2006 Provide for dismissal of all lawsuits and claims related to Impax Paragraph IV filings for generic versions of Shire’s Adderall ® XR Market entry date no later than January 1, 2010 Earlier launch if another generic launches prior to January 1, 2010 Exclusive

  20. Slide 20: Brand Projects

    Targeting improved versions of existing chemical entities Reduced risk and expense associated with development as compared to NCE development. Reduced time of development as compared to NCE development Utilize development and drug delivery expertise Improve patient compliance and outcomes 20 Novembe

  21. Slide 21: Brand Projects: Focus on CNS Drugs

    Focus on Central Nervous System (CNS) drugs Rapidly growing therapeutic area Focus on CNS disease states, including movement disorders such as Parkinson’s disease. These movement disorders are frequently treated by the approximately 8,300 practicing neurologists, of which about 3,500 write the major

  22. Slide 22: Brand Projects: Unmet Needs in Parkinson's Disease

    Despite being the standard for treating Parkinson’s Disease, existing levodopa therapy does not meet certain needs: Delayed or unpredictable “on” Motor fluctuation and dyskinesias Pill burden True delivery of continuous dopaminergic stimulation 22 November 2006 v1 IMPAX Laboratories, Inc. Brand Proj

  23. Slide 23: Brand Projects: VADOVA

    VADOVA TM (carbidopa-levodopa) is formulated with the goal of meeting one of these unmet needs by allowing a reduction in pill burden. 23 November 2006 v1 IMPAX Laboratories, Inc. Brand Projects

  24. Slide 24: Brand Projects: VADOVA NDA Status

    The effective date of acceptance of the VADOVA NDA by FDA was May 3, 2005. The application contained a Paragraph III certification which prevents any approval from becoming effective prior to June 16, 2006. “Non-approvable” letter received from FDA March 3, 2006. Meeting held and response expected 4

  25. Slide 25: Strategic Alliances for Branded Projects: Carbatrol (Shire)

    Signed January 2006 Three year exclusive agreement Payments of $40 million to be received over three years to provide promotional services Target audience – Neurologists Formation of Impax Pharmaceuticals Sales Force and launched product – July 2006 Promoted Product: Carbatrol ® (carbamazepine exten

  26. Slide 26: Significant Milestones

    6 10 3 11 9 8 1 2 Approvals (Total) 4 6 8 8 8 8 Applications Filed *Includes amendments to two previously filed applications—not included in 2005 applications filed 26 November 2006 v1 IMPAX Laboratories, Inc. Significant Milestones Vedco, Dava 3* 2005 IND filings Shire Leiner Andrx / Teva Wyeth, Sc

  27. Slide 27: Cash and Debt Balances

    75,000 86,000 86,000 Cash and Investments 56,077 30,692 27,355 Senior Debt 5,396 5,342 5,316 Convertible Subordinated Debt Total Senior & Convertible Debt 80,396 91,342 91,316 Capital Expenditures 15,095 12,886 4,925 (12 months) (6 months) (3 months) (1) Settlement of Solvay litigation reached 2Q 20

  28. Slide 28: Highlights

    Experienced management with strong industry knowledge and technical expertise Broad base of drug delivery technology, formulation and development expertise Strong product portfolio Branded product strategy offers potential additional long-term growth opportunities 28 November 2006 v1 IMPAX Laborator

  29. Slide 29: Thank you for your interest in IMPAX Laboratories, Inc

    Thank you for your interest in IMPAX Laboratories, Inc 29 November 2006 v1 IMPAX Laboratories, Inc.

Impax Laboratories — Investor Presentation (November 2006) on 6ix